Literature DB >> 2513138

The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.

G E Kim1, C W Song.   

Abstract

The effects of Fluosol-DA, an oxygen-carrying perfluorochemical emulsion, and carbogen breathing alone or in combination on the antitumor activity of cyclophosphamide (CTX) in vivo were investigated. The addition of 12 ml/kg Fluosol-DA immediately prior to CTX treatment exerted no effect on the antitumor effect of CTX on the RIF-1 tumor in C3H mice. On the other hand, carbogen breathing alone for 8 h significantly enhanced the antitumor effect of CTX, with a dose-modification factor of 1.29 +/- 0.07. The combination of Fluosol-DA and carbogen breathing further increased the effect of CTX, with a dose-modification factor of 1.63 +/- 0.05. There was no significant difference in animal lethality within the treatment groups. It was concluded that Fluosol-DA in combination with carbogen breathing may be useful for the enhancement of CTX chemotherapy of human neoplasms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513138     DOI: 10.1007/bf00692347

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen.

Authors:  C W Song; I Lee; T Hasegawa; J G Rhee; S H Levitt
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

2.  Effect of a perfluorochemical emulsion on the development of artificial lung metastases in mice.

Authors:  S Rockwell; C G Irvin; M Nierenburg
Journal:  Clin Exp Metastasis       Date:  1986 Jan-Mar       Impact factor: 5.150

3.  Increases in brain tumor and cerebral blood flow by blood-perfluorochemical emulsion (Fluosol-DA) exchange.

Authors:  S Hiraga; P Klubes; E S Owens; R L Cysyk; R G Blasberg
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

4.  Effects of Fluosol DA 20% and carbogen on the radioresponse of SCK tumors and skin of A/J mice.

Authors:  I Lee; S H Levitt; C W Song
Journal:  Radiat Res       Date:  1987-10       Impact factor: 2.841

5.  Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.

Authors:  B A Teicher; J M Crawford; S A Holden; K N Cathcart
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

6.  Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.

Authors:  B A Teicher; S A Holden
Journal:  Cancer Treat Rep       Date:  1987-02

7.  Effects of hypoxia, pH, and growth stage on cell killing in Chinese hamster V79 cells in vitro by activated cyclophosphamide.

Authors:  A C Begg; D C Shrieve; K A Smith; N H Terry
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

8.  Acute effects of a perfluorochemical oxygen carrier on normal tissues of the mouse.

Authors:  K A Mason; H R Withers; R J Steckel
Journal:  Radiat Res       Date:  1985-12       Impact factor: 2.841

9.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor.

Authors:  S Rockwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-01       Impact factor: 7.038

View more
  2 in total

1.  A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.

Authors:  B A Teicher; S A Holden; G Ara; C S Ha; T S Herman; D Northey
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.

Authors:  B A Teicher; T S Herman; R E Hopkins; K Menon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.